In some studies, half of patients stopped taking GLP-1s within a year despite the benefits, citing the expense and side ...

Healthy snacks are in demand as meals are being “swapped for grazing” as the rise of weight-loss jabs encourages a “change in ...

Eli Lilly ( LLY 2.00%) recently announced stellar results from a phase 3 clinical trial, Triumph-4, which evaluated efficacy ...

Popular new anti-obesity medications can help people lose 10% to 20% of their body weight, yet a new study indicates that ...

With foodborne illnesses and changes in Medicare and Medicaid coverage, University of Virginia (UVA) Health experts say never ...

Intentional spending doesn't automatically translate into a single-minded hunt for the lowest prices or loyalty-led discounts ...

UnitedHealth Group has had a tumultuous year, marred by poor performance and controversy. Eli Lilly has thrived as it's taken ...

Eli Lilly's next-gen anti-obesity candidate hit it out of the park in a phase 3 study. This should help solidify the ...

Lilly's Zepbound price cuts ranged from $50 to $100, depending on the dosage, for consumers who pay cash via the drugmaker's ...

Obesity is a big driver of healthcare spending in South Africa, yet most medical schemes still limit cover for effective treatments. The gap between the scale of the problem and the funding response ...

The Mumbai-based drugmaker, in a regulatory filing, said it has the rights to distribute and promote Yurpeak, the second anti ...

B by the mid-2030s, driven by GLP-1/GIP drugs and expanding access beyond the U.S. ・Lilly strengthens its leadership with a deep pipeline, while Novo faces slowing growth, price cuts, and ...